In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

American Century Companies Inc. gave Amgen a financial haircut, slashing its stake by 46.3% and cashing in $36.76 million.

The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...

Quantbot Technologies LP boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 219.5% during the fourth ...

Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy ...

Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business ...

On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The ongoing investigation by Wyden and his Democratic compatriots from the Finance Committee has pointed the finger at ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...